QLI Stock Overview
Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Qilian International Holding Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.74 |
| 52 Week High | US$1.30 |
| 52 Week Low | US$0.36 |
| Beta | 1.52 |
| 1 Month Change | 29.03% |
| 3 Month Change | 41.31% |
| 1 Year Change | -37.70% |
| 3 Year Change | -83.77% |
| 5 Year Change | n/a |
| Change since IPO | -92.65% |
Recent News & Updates
Recent updates
Earnings Not Telling The Story For Qilian International Holding Group Limited (NASDAQ:QLI) After Shares Rise 79%
Dec 31
Qilian International Non-GAAP EPS of $0.01, revenue of $32.09M
Oct 03We Think You Can Look Beyond Qilian International Holding Group's (NASDAQ:QLI) Lackluster Earnings
Sep 23Qilian International signs Gan Di Xin's exclusive distribution agreement
May 05Qilian International Holding Group Limited's (NASDAQ:QLI) Share Price Matching Investor Opinion
Apr 12Shareholder Returns
| QLI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 5.2% | -1.5% | -3.2% |
| 1Y | -37.7% | 9.7% | 19.3% |
Return vs Industry: QLI underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: QLI underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| QLI volatility | |
|---|---|
| QLI Average Weekly Movement | 19.3% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: QLI's share price has been volatile over the past 3 months.
Volatility Over Time: QLI's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 298 | Zhanchang Xin | www.qlsyy.net |
Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications.
Qilian International Holding Group Limited Fundamentals Summary
| QLI fundamental statistics | |
|---|---|
| Market cap | US$27.17m |
| Earnings (TTM) | -US$7.78m |
| Revenue (TTM) | US$46.47m |
0.6x
P/S Ratio-3.4x
P/E RatioIs QLI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QLI income statement (TTM) | |
|---|---|
| Revenue | US$46.47m |
| Cost of Revenue | US$44.72m |
| Gross Profit | US$1.75m |
| Other Expenses | US$9.53m |
| Earnings | -US$7.78m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 3.77% |
| Net Profit Margin | -16.74% |
| Debt/Equity Ratio | 1.1% |
How did QLI perform over the long term?
See historical performance and comparison